01—Abstract
Summary
Summary of the 10-Q filed November 30, 2023. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc reported solid financial results for the second quarter of fiscal year 2024, with net sales increasing by 5% to $7.98 billiona and diluted earnings per share (EPS) of $0.68 compared to $0.32 in the prior year quarter.
For the six-month period, net sales grew 5% to $15.69 billionb, and diluted EPS was $1.28, up from $1.02 in the prior year. The company demonstrated continued revenue growth across its key segments, including Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, driven by strong performance in specific product lines like Micra, TAVR, Core Spine, and the MiniMed 780G insulin pump system. Despite facing inflationary pressures and supply chain challenges, Medtronic maintained its commitment to innovation and strategic growth initiatives, including pending acquisitions and new product launches, positioning the company for sustained performance.
02—Key points
Key Highlights
- Net sales increased by 5% to $7.98 billion for the second quarter of fiscal year 2024, and by 5% to $15.69 billion for the first six months.
- Diluted Earnings Per Share (EPS) was $0.68 for the quarter, a significant increase from $0.32 in the prior year, and $1.28 for the six-month period, up from $1.02.
- All four major business segments (Cardiovascular, Neuroscience, Medical Surgical, and Diabetes) showed year-over-year revenue growth.
- The Cardiovascular segment saw a 6% increase in net sales, driven by products like Micra and TAVR.
- The Neuroscience segment's net sales grew 5%, with strong contributions from Core Spine and Neurosurgery.
- The Diabetes segment reported a 10% increase in net sales for the quarter, driven by the MiniMed 780G insulin pump system's global expansion.
- Medtronic repurchased approximately 2.3 million shares for $186 million during the fiscal second quarter under its $6.0 billion share repurchase program, with approximately $2.0 billion remaining.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Medtronic plc kept $0.11.
- Revenue$7.98B100.0%
- Cost of revenue−$2.76B34.6%
- Gross profit$5.22B65.4%
- Operating costs−$3.88B48.6%
- Operating income$1.34B16.8%
- Interest, other & tax−$429.0M5.4%
- Net income$911.0M11.4%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed November 30, 2023Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $7.98B$7.58B | +5.3% |
| Cost of Revenue | $2.76B$2.54B | +8.9% |
| Gross Profit | $5.22B$5.05B | +3.4% |
| SG&A Expenses | $2.69B$2.62B | +2.6% |
| Operating Income | $1.34B$1.40B | −4.6% |
| Interest Expense | $180.00M$118.00M | +52.5% |
| Net Income | $911.00M$435.00M | +109.4% |
| EPS (Basic) | $0.68$0.32 | +112.5% |
| EPS (Diluted) | $0.68$0.32 | +112.5% |
| Shares Outstanding (Basic) | 1.33B1.33B | +0.1% |
| Shares Outstanding (Diluted) | 1.33B1.33B | 0.0% |
05—Questions
Frequently Asked Questions
What was Medtronic's overall revenue performance in the reported quarter?
Medtronic reported a 5% increase in net sales for the second quarter of fiscal year 2024, reaching $7.98 billion, compared to $7.59 billion in the same period last year. This growth was driven by increases across most product lines and businesses.
How did Medtronic's profitability change in this quarter?
Profitability saw a significant improvement. Diluted earnings per share (EPS) more than doubled to $0.68 from $0.32 in the prior year's second quarter. For the six-month period, diluted EPS increased to $1.28 from $1.02.
Which business segments performed best?
All four major segments showed growth. The Diabetes segment had a notable 10% increase in net sales for the quarter, driven by the international expansion of the MiniMed 780G insulin pump system. Cardiovascular and Medical Surgical segments both grew by 6% and 7% respectively for the quarter, while Neuroscience saw a 5% increase.
What are Medtronic's key growth drivers for the future?
Medtronic's future growth is expected to be driven by continued adoption of key products such as the Micra transcatheter pacing system, TAVR devices, the MiniMed 780G insulin pump system, and advancements in their neuroscience portfolio. The company also continues to invest in R&D and pursue strategic acquisitions.
How is Medtronic managing its share repurchases and capital allocation?
Medtronic repurchased approximately 2.3 million shares for $186 million during the fiscal second quarter, as part of its ongoing $6.0 billion share repurchase program. Approximately $2.0 billion remains authorized for future repurchases, indicating a continued focus on returning value to shareholders.
06—Continue